A fourfold reduction in the rate of asymptomatic SARS-CoV-2 infection in healthcare workers ≥12 days after a single dose of BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) has been found.

The BNT162b2 mRNA COVID-19 vaccine is highly effective at generating immune responses in people over the age of 80 years and provides good cross neutralization of the P.1 gamma variant of concern.

Third SARS-CoV-2 vaccination appears to eliminate disparities in anti-Spike antibodies between those who received Pfizer-BioNTech versus Oxford/AstraZeneca for first and second vaccination, but levels remain lower in certain groups such as those on the UK 'Shielded Patient List'.

During the COVID-19 pandemic, cancer-related screening and healthcare practices varied (by age, race/ethnicity, education, and comorbidities), and considering these differences in high-risk individuals' monitoring is important as undiagnosed cases or poor prognosis may increase due to delayed screening/treatment.

Immune markers measured at the early stage of COVID-19 infection are associated with various clinical outcomes and can be used to predict disease progression, T cell memory, viral shedding, and the antibody response of the COVID-19 patients.

SARS-CoV-2 infection and vaccination elicit antibodies that cross-react with other human coronavirus spike proteins, indicating the spike S2 subdomain as a potential target strategy to develop a pan-coronavirus vaccine.

The new early warning system, COEWS, will improve the early identification and management of high-risk COVID-19 patients compared to the widely used NEWS2 by using easy-to-obtain clinical parameters that have been externally validated in a diverse multicontinental cohort of patients.

Serum antibodies induced by CoronaVac tended to decrease over time, even though vaccinated with the homologous booster dose, and Delta and Omicron variants may be able to more efficiently evade the antibodies with time.

COVID-19 mRNA vaccine-elicited T cells recognize variants of concern and phenotypically differ depending on number of vaccine doses and prior SARS-CoV-2 infection status.

Sera from vaccinated subjects bound additional linear epitopes compared to sera from individuals with mild infection, in addition the pathways of escape from antibodies from vaccination were more uniform than those from mildly infected individuals.